Stockscreener 앱 받기
11.36
0.71%
0.08
시간 외 거래:
11.52
0.16
+1.41%
전일 마감가:
$11.28
열려 있는:
$11.38
하루 거래량:
1.02M
Relative Volume:
0.60
시가총액:
$1.46B
수익:
-
순이익/손실:
$-45.86M
주가수익비율:
-30.60
EPS:
-0.3713
순현금흐름:
$-44.02M
1주 성능:
+11.48%
1개월 성능:
+13.71%
6개월 성능:
+56.04%
1년 성능:
+151.33%
1일 변동 폭
$11.35
$11.74
1주일 범위
$9.82
$11.74
52주 변동 폭
$4.17
$14.39
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
11.36 | 1.45B | 0 | -45.86M | -44.02M | -0.3713 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect? - Finviz
EV Market: Can Trevi Therapeutics Inc continue delivering strong returnsWeekly Trade Report & Risk Managed Investment Entry Signals - baoquankhu1.vn
Will Trevi Therapeutics Inc. outperform its industry peersJuly 2025 Volume & AI Driven Stock Price Forecasts - mfd.ru
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Trevi Therapeutics Executives to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Promising 99% Potential Upside In Biotech - DirectorsTalk Interviews
Can Trevi Therapeutics Inc. disrupt its industryDay Trade & Safe Investment Capital Preservation Plans - mfd.ru
Is Trevi Therapeutics Inc. stock resilient to inflationGold Moves & Fast Entry High Yield Stock Tips - mfd.ru
New Haven biotech Trevi Therapeutics builds billion-dollar valuation around lone late-stage cough drug - Hartford Business Journal
Fed Watch: Can Trevi Therapeutics Inc continue delivering strong returns2025 Market Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Encompass Health (EHC), Hims & Hers Health (HIMS) and Trevi Therapeutics (TRVI) - The Globe and Mail
Aug Outlook: How does Trevi Therapeutics Inc compare to its peersQuarterly Earnings Summary & AI Driven Price Predictions - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Brokerages - Defense World
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN
Tejara Capital Ltd Trims Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Advances Toward Treatment for Debilitating Cough - AD HOC NEWS
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Strong Buy Ratings and Nearly 100% Upside Potential - DirectorsTalk Interviews
Will Trevi Therapeutics Inc. benefit from rate cutsJuly 2025 Review & Technical Confirmation Trade Alerts - mfd.ru
Can Trevi Therapeutics Inc. continue delivering strong returnsWeekly Profit Analysis & High Accuracy Trade Alerts - mfd.ru
ETF Watch: Is Nabors Industries Ltd showing insider buyingTrade Exit Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Weekly Recap: Does Trevi Therapeutics Inc offer margin of safetyShort Setup & Verified High Yield Trade Plans - baoquankhu1.vn
Coulter Partners Recruits CFO for Trevi Therapeutics - Hunt Scanlon Media
Is Trevi Therapeutics Inc a momentum stockEarnings Performance Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Trevi Therapeutics Advances Toward Key Regulatory Review Following Clinical Validation - AD HOC NEWS
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.5%Here's Why - MarketBeat
Trevi Therapeutics (TRVI) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Trevi Therapeutics Reports Positive Results on Treatment for Chronic Cough; Shares Rise - marketscreener.com
Trevi Therapeutics (TRVI) Publishes Positive Phase 2b Trial Resu - GuruFocus
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) - PR Newswire
Aug Action: Is Trevi Therapeutics Inc a top pick in the sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Trevi Therapeutics Inc. stock technically oversoldBear Alert & Accurate Buy Signal Alerts - bollywoodhelpline.com
New trial links cough counts to how IPF patients feel on oral treatment - Stock Titan
Will Trevi Therapeutics Inc outperform tech stocksPortfolio Gains Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
Coulter Partners successfully led a search assignment for Trevi Therapeutics, Inc. (Nasdaq: TRVI) and is pleased to announce the placement of David Hastings as Chief Financial Officer (CFO) - Hunt Scanlon Media
Trevi Therapeutics (TRVI) targets next phase of growth with leadership change - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of “Buy” by Brokerages - Defense World
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism - Yahoo Finance
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? - Yahoo Finance
Peregrine Capital Management LLC Invests $5.68 Million in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at HC Wainwright - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from HC Wainwright - MarketBeat
Trevi Therapeutics (TRVI) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | TRVI Stock News - GuruFocus
Trevi Therapeutics’ (TRVI) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Sahm
Published on: 2026-01-09 09:26:05 - Улправда
Will Trevi Therapeutics Inc. stock maintain momentum in 2025Quarterly Growth Report & Long Hold Capital Preservation Plans - Улправда
Will Trevi Therapeutics Inc. stock split again soonJuly 2025 Macro Moves & Community Consensus Trade Alerts - Улправда
Growth Value: Can Trevi Therapeutics Inc. stock maintain growth trajectoryProfit Target & Verified Entry Point Signals - ulpravda.ru
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.68%
자본화:
|
볼륨(24시간):